Lenskart Solutions Limited LENSKART NIFTY_MIDNSEPHARMA
Company Overview
Lenskart Solutions Limited, a technology-driven eyewear company, engages in designing, manufacturing, branding, and retailing of eyewear products in India, Japan, Southeast Asia, the Middle East, and internationally. Its products include prescription eyeglasses, sunglasses, goggles, screen glasses, and other products, such as contact lenses and eyewear accessories, including frames for men, women, and kids. The company also engages in lens manufacturing, lens edging, lens design, frame design, frame manufacturing, and delivery. It operates as a direct-to-consumer company that designs and sells a wide range of eyewear products under the Lenskart and Owndays brands; and sub brands, including John Jacobs, Vincent Chase, Hooper, Lenskart Air, Hustlr, LPL, and Meller. It sells its products through online and offline channels, such as retail stores, websites, mobile applications, and other channels. The company also owns and operates eyewear retail stores in India and provides home eye check-up services. Lenskart Solutions Limited was incorporated in 2008 and is based in Gurugram, India.
Why Investors Should Care
Net profit has compounded at 67.0% per year over the last five years.
Revenue has grown at a 35.4% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.35.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹8,789.86 Cr (+35.4% YoY); net profit ₹493.61 Cr.
- Trailing 12 Months Year-on-year growth — revenue +43.3%, earnings +258.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 35.4%, profit CAGR 67.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 35.38% |
| 1 Year: | 43.30% |
Compounded Profit Growth
| 5 Years: | 66.99% |
| 1 Year: | 258.10% |
Stock Price Performance
| 1 Year: | +56.62% |
| 6 Months: | +20.39% |
| 3 Months: | +13.27% |
| 1 Month: | -7.68% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)38.68 · Neutral
P/E of 164.41 is above the sector median of 36.43 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 35.4% over 5 years.
- Profit CAGR of 67.0% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 164.4.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 631.35 | 164.41 | ₹1.09 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,745.10 | 34.62 | ₹4.19 L Cr | 0.91% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,190.00 | 83.58 | ₹2.44 L Cr | 0.32% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,553.80 | 72.74 | ₹1.73 L Cr | 0.81% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,117.30 | 24.90 | ₹1.11 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 6 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 7,600.00 | 52.32 | ₹1.09 L Cr | 0.25% | 19.20% | 20.48% | 14.85% | 33.34% |
| 7 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 2,012.50 | 99.48 | ₹1.09 L Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,314.00 | 31.51 | ₹1.06 L Cr | 0.99% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,244.50 | 31.32 | ₹1.04 L Cr | 0.66% | 14.22% | 8.84% | 10.96% | -1.67% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,736.00 Cr | - | 1,727.57 Cr | 1,894.46 Cr | 2,096.00 Cr | 2,307.73 Cr | 2,515.71 Cr | 2,714.18 Cr |
| Cost of Revenue | - | - | 560.44 Cr | 604.03 Cr | - | 717.01 Cr | 764.46 Cr | 807.25 Cr |
| Gross Profit | - | - | 1,167.13 Cr | 1,290.43 Cr | - | 1,590.72 Cr | 1,751.24 Cr | 1,906.93 Cr |
| Operating Expenses | 1,449.00 Cr | - | 1,089.41 Cr | 1,191.51 Cr | 1,683.00 Cr | 1,396.92 Cr | 1,500.33 Cr | 1,623.08 Cr |
| Operating Income | 90.00 Cr | - | 77.72 Cr | 98.92 Cr | 160.00 Cr | 193.80 Cr | 250.91 Cr | 283.85 Cr |
| EBITDA | 286.00 Cr | - | 503.44 Cr | 377.89 Cr | 413.00 Cr | 497.46 Cr | 585.25 Cr | 657.43 Cr |
| Interest Expense | 26.00 Cr | - | 47.51 Cr | 41.04 Cr | 45.00 Cr | 48.71 Cr | 43.54 Cr | 53.19 Cr |
| Pretax Income | 134.00 Cr | - | 240.78 Cr | 99.72 Cr | 148.00 Cr | 178.42 Cr | 254.19 Cr | 299.61 Cr |
| Tax Provision | 48.24 Cr | - | 20.65 Cr | 38.55 Cr | 44.40 Cr | 45.71 Cr | 50.58 Cr | 71.18 Cr |
| Net Income | 86.00 Cr | - | 218.88 Cr | 60.08 Cr | 103.00 Cr | 131.03 Cr | 200.28 Cr | 221.84 Cr |
| Diluted EPS | 11.08 | - | 1.27 | 0.35 | 1.24 | 0.77 | 1.16 | 1.28 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | 905.00 Cr | 1,503.00 Cr | 3,788.00 Cr | 5,428.00 Cr | 6,492.68 Cr | 8,789.86 Cr |
| Cost of Revenue | - | - | - | - | 2,163.80 Cr | 2,776.10 Cr |
| Gross Profit | - | - | - | - | 4,328.88 Cr | 6,013.76 Cr |
| Operating Expenses | 952.00 Cr | 1,617.00 Cr | 3,524.00 Cr | 4,748.00 Cr | 4,276.00 Cr | 5,238.93 Cr |
| Operating Income | -86.00 Cr | -200.00 Cr | -154.00 Cr | 8.00 Cr | 52.88 Cr | 774.83 Cr |
| EBITDA | -47.00 Cr | -115.00 Cr | 264.00 Cr | 680.00 Cr | 1,327.82 Cr | 1,907.17 Cr |
| Interest Expense | 7.00 Cr | 23.00 Cr | 83.00 Cr | 124.00 Cr | 145.89 Cr | 178.45 Cr |
| Pretax Income | 33.00 Cr | -108.00 Cr | -97.00 Cr | 59.00 Cr | 385.36 Cr | 680.33 Cr |
| Tax Provision | 0 | -0 | 37.83 Cr | 69.03 Cr | 88.02 Cr | 179.38 Cr |
| Net Income | 29.00 Cr | -102.00 Cr | -64.00 Cr | -10.00 Cr | 295.59 Cr | 493.61 Cr |
| Diluted EPS | 3.79 | -13.39 | -8.34 | -2.26 | 1.72 | 2.90 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Total Assets | 2,802.00 Cr | 3,700.00 Cr | - | - | 10,471.02 Cr | 14,413.32 Cr |
| Current Assets | - | - | - | - | 3,630.03 Cr | 5,670.43 Cr |
| Cash & Equivalents | - | - | - | - | 654.22 Cr | 973.30 Cr |
| Inventory | - | - | - | - | 1,081.44 Cr | 1,037.00 Cr |
| Receivables | - | - | - | - | 125.89 Cr | 174.72 Cr |
| Total Liabilities | - | - | - | - | 4,264.85 Cr | 5,561.58 Cr |
| Current Liabilities | - | - | - | - | 1,868.55 Cr | 2,507.56 Cr |
| Long Term Debt | - | - | - | - | - | 133.57 Cr |
| Total Debt | 30.00 Cr | 34.00 Cr | - | - | 2,572.77 Cr | 3,096.60 Cr |
| Total Equity | 2,378.00 Cr | 2,933.00 Cr | - | - | 6,098.73 Cr | 8,738.51 Cr |
| Shares Outstanding | - | - | 172.76 Cr | 172.76 Cr | 172.76 Cr | 173.64 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -117.00 Cr | -183.00 Cr | 95.00 Cr | 487.00 Cr | - | 1,669.59 Cr |
| Investing Cash Flow | 115.00 Cr | -421.00 Cr | -2,586.00 Cr | 163.00 Cr | - | -2,724.80 Cr |
| Financing Cash Flow | -16.00 Cr | 604.00 Cr | 2,777.00 Cr | -722.00 Cr | - | 1,200.52 Cr |
| Capital Expenditure | -110.00 Cr | -247.00 Cr | -413.00 Cr | -432.00 Cr | - | -828.47 Cr |
| Free Cash Flow | -227.00 Cr | -430.00 Cr | -318.00 Cr | 55.00 Cr | - | 841.13 Cr |
| Net Change in Cash | -18.00 Cr | 0 | 285.00 Cr | -72.00 Cr | - | 145.31 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 66.7% | 68.4% |
| Operating Margin % | -9.5% | -13.3% | -4.1% | 0.1% | 0.8% | 8.8% |
| Net Margin % | 3.2% | -6.8% | -1.7% | -0.2% | 4.6% | 5.6% |
| ROE % | 1.2% | -3.5% | - | - | 4.8% | 5.6% |
| ROCE % | - | - | - | - | 0.6% | 6.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LENSKART
Price Performance - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE50YkFOQVJsLWVjUTU3WW0yNWVhdFZHRTd1TklOR1dBbEF4N0g0V2VReEFSdTUtbGRzeUxzTkUxeElDMkJUeDNKcWpHMi05YW1fcWdUZUFDbU9mLTNp?oc=5" target="_blank">Price Performance</a> <font colo…
Lenskart stock falls 4% as shares worth Rs 1,895 crore change hands in block deals; Alpha Wave likely seller - TradingView
<a href="https://news.google.com/rss/articles/CBMi_gFBVV95cUxNQkhGVEJRNTBUZmdSN0lNVHhacnU3QVUzNDhlWXlDSXU5UmpHclNYSGllalVMLU0xVkphMzd0ZUswZnBscnNxNjBCSWZ4U29DTW1ZOF9lUEh1aU9YNG1JWnh1eEFGMERPeFNzWUg4TnhMR3Z6NUlmOVBmRHdzWHR3QWtMVUIxVEo1dUJpd1…
Lenskart stock falls 4% as shares worth Rs 1,895 crore change hands in block deals; Alpha Wave likely seller- Moneycontrol.com - LinkedIn
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOcENFVUVVUHV3SGNkQnczZ25DYWNyRlJkX1lXNWplTVNYaVdOYlBTZkZQMGdqd0Z2QjgwWFh5Y1U4ZEcyRW02RW1DazNHLUdkaFRjRlc0X2oxaGp5RkJKanRaazd6WlAxRWJHQmJlYjU5THFxVEo2eGxESHZyUkdldDVkT2N4cXpJQVlsS2…
Lenskart stock regains clarity after short dip on Abu Dhabi Investment Authority stake sale - The Week
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOWllMcVVhR0N6aEwwQlhudkRsejlQRGdqeEF1Y1dxcjRmRUxRRVB3bEZYWHBFb1Y0QmNXeVV5MHpsVWRaYlJoM05TVFZSVFVweFowUFlKenJEMTl1VDVxT21YQkloTV9ES2dwNlJIeTdtRlZUc0FpeElaam1SdFpPb3Z5S2lXczRmcDRmMj…
Lenskart Solutions shares crack 5% after Rs 1,985-crore block deal; Alpha Wave likely sells take - The Economic Times
<a href="https://news.google.com/rss/articles/CBMi-wFBVV95cUxPMDdqcnpiZlBXdE5faVRyWEVEUVNUMWFBekxFalU2cV9Qa3hQbUwzR1l0blhXSG5LNU5samtjNXh1bVlYZkpMS0tWbFNReHlONzFBX25UNEFpenBKMTNtbTNfelpOc2hjbDNTQTlyelhpMXhubmhSZWJjNkRGaHVmMmIwU2p1UUVJcFJGV0…
Lenskart Shares Slump 5% Amid Bulk Deal Buzz - Inc42
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE1pZWFJRWNiWkJkaDFhZllzM1RNaktydk1uU1RuUmt0QmtibkxWYmJ5VUwxU2JUbGh4REtxOFVNSWdTcVo1bmI2YW1jR25DZG90VzQzbXBlOE1JUk9MNkwwM29oMFE2d2VDMjlVeTFCbWFmcTdjQ3c?oc=5" target="_blank">Lenskart…
LENSKART — Frequently Asked Questions
What is the current share price of Lenskart Solutions Limited (LENSKART)?
As of 2026-10-23 04:58 IST, Lenskart Solutions Limited (LENSKART) trades at ₹631.35 on NSE. Its 52-week range is ₹400.15 to ₹707.20.
What is the market capitalisation of LENSKART?
Lenskart Solutions Limited (LENSKART) has a market capitalisation of ₹1.09 L Cr on NSE.
What is the P/E ratio of LENSKART?
LENSKART trades at a trailing price-to-earnings (P/E) ratio of 164.41. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 13.47.
What is the return on equity (ROE) of LENSKART?
LENSKART has a return on equity (ROE) of 5.65%. Its return on capital employed (ROCE) is 7.21%.
Is LENSKART a good stock to buy?
This page provides a data-driven analysis of Lenskart Solutions Limited (LENSKART), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.